{"id":"8b084e4e-67b0-5d1d-ad43-20ed7f7dac67","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-human-combined-cd38-null","predicate":"no_detected_change_in_recorded_comparison","statement":"PBMC CD38 protein abundance did not change detectably during the 2024 combined-product trial.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"4ecef011-2f46-5ed1-9fd8-5f82fb8afe43","mechanism_event_label":"PBMC CD38 protein abundance did not change detectably during the 2024 combined-product trial.","subject":{"id":"3b9d39d2-dcd2-5453-b25f-2ec41fc3f10b","slug":"nuchido-time-plus-2024","display_name":"Nuchido TIME+ multicomponent preparation in the 2024 trial","entity_type_key":"chemical_species"},"object":{"id":"fddfde71-6536-5ac2-82cd-5942ad68b116","slug":"cd38","display_name":"Human CD38","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"4ecef011-2f46-5ed1-9fd8-5f82fb8afe43","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-human-combined-cd38-null-event","event_type":"experimental_observation","label":"PBMC CD38 protein abundance did not change detectably during the 2024 combined-product trial.","description":"### api-human-combined-cd38-null\n\nPBMC CD38 protein abundance did not change detectably during the 2024 combined-product trial.\nProtein amount is not enzyme activity; this does not measure direct apigenin occupancy or CD38 inhibition.\nModel and exposure: PBMC protein assays; 28-day intervention.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: The use of a systems approach to increase NAD<sup>+</sup> in human participants. | 2024 | https://pubmed.ncbi.nlm.nih.gov/38302501/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10834541/ | https://doi.org/10.1038/s41514-023-00134-0 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"3b9d39d2-dcd2-5453-b25f-2ec41fc3f10b","slug":"nuchido-time-plus-2024","display_name":"Nuchido TIME+ multicomponent preparation in the 2024 trial","entity_type_key":"chemical_species"},"role":"tested factor","stoichiometry":null,"state_label":"Multicomponent preparation","sequence_order":0,"notes":""},{"entity":{"id":"fddfde71-6536-5ac2-82cd-5942ad68b116","slug":"cd38","display_name":"Human CD38","entity_type_key":"protein"},"role":"measured outcome","stoichiometry":null,"state_label":"no_detected_change","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Multicomponent preparation\", \"comparator\": \"Study baseline/placebo comparisons\", \"endpoint\": \"PBMC CD38 protein abundance did not change detectably during the 2024 combined-product trial.\", \"effect_direction\": \"no_detected_change\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"PBMC protein assays; 28-day intervention.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Apigenin collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"PBMC CD38 protein abundance did not change detectably during the 2024 combined-product trial.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"The use of a systems approach to increase NAD<sup>+</sup> in human participants. | https://pubmed.ncbi.nlm.nih.gov/38302501/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10834541/ | https://doi.org/10.1038/s41514-023-00134-0","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference api-human-combined-cd38-null; Protein amount is not enzyme activity; this does not measure direct apigenin occupancy or CD38 inhibition.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"28c61b79-7592-5c87-ada7-a078b66a62ba","evidence_kind":"source_excerpt","locator":"Lines 508-514","start_line":508,"end_line":514,"excerpt":"### api-human-combined-cd38-null\n\nPBMC CD38 protein abundance did not change detectably during the 2024 combined-product trial.\nProtein amount is not enzyme activity; this does not measure direct apigenin occupancy or CD38 inhibition.\nModel and exposure: PBMC protein assays; 28-day intervention.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: The use of a systems approach to increase NAD<sup>+</sup> in human participants. | 2024 | https://pubmed.ncbi.nlm.nih.gov/38302501/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10834541/ | https://doi.org/10.1038/s41514-023-00134-0 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"PBMC protein assays; 28-day intervention.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"54eac90b-add1-5f56-9036-d900307c5697","stable_key":"import-ff370329-68a3-573d-96ee-597de78a3967","title":"Apigenin: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"ede6e5c6b91d66b66844f2ff667a7f8303d9ac1281f15dc09db703f7de4da942","revision_id":"b41a39a2-0197-549c-97a5-1765e6696931","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}